Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.

导出 OA

翻译打印收藏纠错

作者： Angelika,Borkowetz ^[1] ; Ulrich,Sommer ^[2] ; Gustavo,Baretton ^[2] ; Carsten,Gruellich ^[3] ; Björn Thorben,Bürk ^[3] ; Holger H H,Erb ^[4] ; Christian,Thomas ^[3] ; MORECAB Consortium

作者单位： Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany. Angelika.Borkowetz@ukdd.de.;German Cancer Consortium (DKTK), Site, Dresden, Germany. Angelika.Borkowetz@ukdd.de. ^[1] Institute of Pathology, University Hospital, Technische Universität Dresden, Dresden, Germany. ^[2] Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany. ^[3] Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.;German Cancer Consortium (DKTK), Site, Dresden, Germany. ^[4]

关键词 Cabozantinib Genomic alterations Metastatic renal cell carcinoma

主题词人类(Humans);癌, 肾细胞(Carcinoma, Renal Cell);肾肿瘤(Kidney Neoplasms);基因组学(Genomics);DNA(DNA);酰苯胺类(Anilides);吡啶类(Pyridines)

DOI 10.1007/s00345-024-04783-y

PMID 38386122

发布时间 2025-01-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交